A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis

Y. Suzuki, T. Matsumoto, Shinichiro Okamoto, T. Hibi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: To assess the safety and efficacy of lecithinized superoxide dismutase (PC-SOD) in patients with ulcerative colitis (UC). Method: PC-SOD was injected once daily at doses of 40 mg (n = 22) and 80 mg (n = 20) for a total treatment period of 4 weeks. Efficacy was assessed by UC-Disease Activity Index (DAI) total score. All side effects were recorded and investigated. Results: At 4 weeks, the UC-DAI total score was significantly decreased vs baseline in both the 40 mg and 80 mg groups. It was confirmed that PC-SOD 80 mg was, at least, not significantly superior to PC-SOD 40 mg. Twenty incidences of side effects were noted in 12 (54.55%) of 22 patients in the 40 mg group, while there were three incidences of side effects in two (10.00%) of 20 patients in the 80 mg group. None of these side effects was severe. Thus it was concluded that the test drug is safe when given at daily dosages of 40 mg and 80 mg. Conclusion: In this pilot study PC-SOD improved UC more rapidly than previously existing drugs. A double blind, placebo-controlled clinical trial of PC-SOD 40mg/day is required to confirm the efficacy of this agent against UC.

Original languageEnglish
Pages (from-to)931-934
Number of pages4
JournalColorectal Disease
Volume10
Issue number9
DOIs
Publication statusPublished - 2008

Fingerprint

Ulcerative Colitis
Incidence
Controlled Clinical Trials
Pharmaceutical Preparations
Placebos
lecithinized superoxide dismutase
Safety
Therapeutics

Keywords

  • PC-SOD
  • Superoxide dismutase
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis. / Suzuki, Y.; Matsumoto, T.; Okamoto, Shinichiro; Hibi, T.

In: Colorectal Disease, Vol. 10, No. 9, 2008, p. 931-934.

Research output: Contribution to journalArticle

Suzuki, Y. ; Matsumoto, T. ; Okamoto, Shinichiro ; Hibi, T. / A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis. In: Colorectal Disease. 2008 ; Vol. 10, No. 9. pp. 931-934.
@article{0a3ce08aa69c4bd8bad7ceac8d917393,
title = "A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis",
abstract = "Objective: To assess the safety and efficacy of lecithinized superoxide dismutase (PC-SOD) in patients with ulcerative colitis (UC). Method: PC-SOD was injected once daily at doses of 40 mg (n = 22) and 80 mg (n = 20) for a total treatment period of 4 weeks. Efficacy was assessed by UC-Disease Activity Index (DAI) total score. All side effects were recorded and investigated. Results: At 4 weeks, the UC-DAI total score was significantly decreased vs baseline in both the 40 mg and 80 mg groups. It was confirmed that PC-SOD 80 mg was, at least, not significantly superior to PC-SOD 40 mg. Twenty incidences of side effects were noted in 12 (54.55{\%}) of 22 patients in the 40 mg group, while there were three incidences of side effects in two (10.00{\%}) of 20 patients in the 80 mg group. None of these side effects was severe. Thus it was concluded that the test drug is safe when given at daily dosages of 40 mg and 80 mg. Conclusion: In this pilot study PC-SOD improved UC more rapidly than previously existing drugs. A double blind, placebo-controlled clinical trial of PC-SOD 40mg/day is required to confirm the efficacy of this agent against UC.",
keywords = "PC-SOD, Superoxide dismutase, Ulcerative colitis",
author = "Y. Suzuki and T. Matsumoto and Shinichiro Okamoto and T. Hibi",
year = "2008",
doi = "10.1111/j.1463-1318.2008.01487.x",
language = "English",
volume = "10",
pages = "931--934",
journal = "Colorectal Disease",
issn = "1462-8910",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis

AU - Suzuki, Y.

AU - Matsumoto, T.

AU - Okamoto, Shinichiro

AU - Hibi, T.

PY - 2008

Y1 - 2008

N2 - Objective: To assess the safety and efficacy of lecithinized superoxide dismutase (PC-SOD) in patients with ulcerative colitis (UC). Method: PC-SOD was injected once daily at doses of 40 mg (n = 22) and 80 mg (n = 20) for a total treatment period of 4 weeks. Efficacy was assessed by UC-Disease Activity Index (DAI) total score. All side effects were recorded and investigated. Results: At 4 weeks, the UC-DAI total score was significantly decreased vs baseline in both the 40 mg and 80 mg groups. It was confirmed that PC-SOD 80 mg was, at least, not significantly superior to PC-SOD 40 mg. Twenty incidences of side effects were noted in 12 (54.55%) of 22 patients in the 40 mg group, while there were three incidences of side effects in two (10.00%) of 20 patients in the 80 mg group. None of these side effects was severe. Thus it was concluded that the test drug is safe when given at daily dosages of 40 mg and 80 mg. Conclusion: In this pilot study PC-SOD improved UC more rapidly than previously existing drugs. A double blind, placebo-controlled clinical trial of PC-SOD 40mg/day is required to confirm the efficacy of this agent against UC.

AB - Objective: To assess the safety and efficacy of lecithinized superoxide dismutase (PC-SOD) in patients with ulcerative colitis (UC). Method: PC-SOD was injected once daily at doses of 40 mg (n = 22) and 80 mg (n = 20) for a total treatment period of 4 weeks. Efficacy was assessed by UC-Disease Activity Index (DAI) total score. All side effects were recorded and investigated. Results: At 4 weeks, the UC-DAI total score was significantly decreased vs baseline in both the 40 mg and 80 mg groups. It was confirmed that PC-SOD 80 mg was, at least, not significantly superior to PC-SOD 40 mg. Twenty incidences of side effects were noted in 12 (54.55%) of 22 patients in the 40 mg group, while there were three incidences of side effects in two (10.00%) of 20 patients in the 80 mg group. None of these side effects was severe. Thus it was concluded that the test drug is safe when given at daily dosages of 40 mg and 80 mg. Conclusion: In this pilot study PC-SOD improved UC more rapidly than previously existing drugs. A double blind, placebo-controlled clinical trial of PC-SOD 40mg/day is required to confirm the efficacy of this agent against UC.

KW - PC-SOD

KW - Superoxide dismutase

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=54949090399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949090399&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1318.2008.01487.x

DO - 10.1111/j.1463-1318.2008.01487.x

M3 - Article

C2 - 18294268

AN - SCOPUS:54949090399

VL - 10

SP - 931

EP - 934

JO - Colorectal Disease

JF - Colorectal Disease

SN - 1462-8910

IS - 9

ER -